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ABSTRACT 
Objective: To estimate antithrombotic effect of antiplatelet drugs, in collagen epinephrine treated swiss mice. Materials and  Methods: Lung damage 
(pulmonary thromboembolism) in swiss mice treated with collagen (1.5 mg/kg) and epinephrine (0.5 mg/kg) by tail vein was studied by assessing 
parameters such as percentage protection. The effect of antiplatelet drugs (30µM oral) on above parameters was investigated .This biochemical 
observations were supplemented by histological examination of lung sections. The data from the dose response studies were subjected to one-way 
ANOVA followed by post hoc Bonferroni's Multiple Comparison test. Results: Administration of antiplatelet drugs (30µM oral) significantly 
increased percentage protection against collagen epinephrine induced pulmonary thromboembolism. Histological examination of l ung sections 
revealed less thrombi generation, after administration of various antiplatelet drugs. Conclusions: The study suggests preventive action of 
antiplatelet drugs in collagen epinephrine induced pulmonary thromboembolism. 
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INTRODUCTION 
A number of thrombosis models have been developed for evaluating 
novel antithrombotic agents. The thrombosis is induced in mice 
employing a very small dose of platelet aggregating agents. This 
model is a useful first step of in vivo antithrombotic efficacy of 
antiplatelet drugs in protecting mice from death or paralysis which 
occur in response to thrombotic challenge. The primary aim of this 
study was to examine the antithrombotic effect of antiplatelet drugs 
in venous thrombosis induced by tail vein injection of collagen and 
epinephrine.Epinephrine is able to potentiate the effects of other 
agonists so that the combination such as (collagen and ADP) is a 
stronger stimulus for platelet activation than agonist alone 
[1].Cilostazol, a phosphodiesterase type III inhibitor that shows 
antiplatelet and vasodilator properties, blockade of only one 
pathway of ADP mediated signaling (for example, by Clopidogrel), 
slow onset of action (for example, of Clopidogrel), interpatient 
response variability with poor inhibition of platelet response in 
some patients (for example, to Clopidogrel) is used clinically as an 
antithrombotic drug in the treatment of peripheral vascular disease. 
Therefore, we compared the antithrombotic effect of control with 
that of cilostazol, clopidogrel, in this model. The platelet collagen 
interaction being a very dynamic field of research is considered as 
an attractive target for anti-platelet drug development. With the 
continuous unravelling of signal transduction pathways of specific 
platelet receptors there remains a scope for more efforts to 
determine the precise description of the synergistic roles of GPIb, 
GPVI, and α2β1, along with a more complete assessment of the role 
of other components of the ECM (endothelial cell membrane) and 
additional platelet integrins. Intravenous administration of collagen 
activates platelets leading to a maximal thrombocytopenia within a 
few minutes. The effect is increased by additional injections of 
epinephrine. Activation of platelets leads to intravasal aggregation 
and temporary sequestration of aggregates in the lungs and other 
organs. Depending on the dose of agonist, this experimentally 
induced reduction of the number of circulating platelets is reversible 
within 60 min after induction. The assay is used to test the inhibitory 
capacity of drugs against thrombocytopenia or leucocytopenia as a 
consequence of in vivo platelet or leukocyte stimulation. 
MATERIALS AND METHODS 
MATERIALS 
Chemicals and Drugs 
The drugs which were utilized in the present study were procured 
from the standard pharmaceutical industries like Nicholas Piramal 
India Limited (NPIL), Mumbai and Zydus Cadila Health Care Limited,  
 
Ahmedabad. Cilostazol (PLETAL) ‐75mg tab, Clopidogrel (NOKLOT) 
‐75mg tab were procured. The chemicals which are utilized are 
Collagen type v, Epinephrine Hcl, Acetic acid and Sodium chloride. 
Experimental Animals 
Male Swiss albino mice (20-25gm) were obtained from Bhopal 
Nobles’ college of Pharmacy, Udaipur (Rajasthan). All the animal 
experiments were subjected to Institutional Animal Ethical 
Committee (IAEC) guidelines and were conducted according to the 
guidelines of Experimental Animal Care issued by the Committee for 
Purpose of Control and Supervision of Experiments on Animals 
(CPCSEA). The animals were housed in polypropylene cages and 
maintained on standard chow diet and water ad libitum and on 
12hr/12hr light-dark cycle at temperature: 25±20C, humidity: 45-
55% and ventilation: 10-12 exchanges/hr. 
METHODS 
Experimental induction of pulmonary thromboembolism  
Pulmonary thromboembolism [2] was induced by a method as 
described [3-5, 20]. Briefly, the compounds to be tested, standard drugs 
or the vehicle were administered by oral route 60 minutes (or at 
different time points) prior to the thrombotic challenge. Ten mice 
were used for evaluating the effect of test compound, while a group 
of 5 mice was used to evaluate the effect of cilostazol or vehicle. A 
mixture of collagen (150μg/ml) and epinephrine (50μg/ml) was 
injected into the tail vein to achieve final doses of collagen (1.5 
mg/kg) and epinephrine (0.5 mg/kg) to induce hind limb paralysis 
or death. 
Histology and electron microscopy of collagen epinephrine 
induced pulmonary thromboembolism of mouse lung 
Histology of the lung determines whether the vessels of 
microcirculation of these thrombi consist collagen epinephrine 
injection. The animals which are not dying noted as protected and 
which are losses their righting reflex is noted as paralyzed. The 
animals which not die anesthetize with ether and immediately 
perfused with perfusion with phosphate-buffered saline (PBS) and 
neutral buffer formalin 10% after the end of fixative perfusion lung 
excised and post-fixed in 10% NBF overnight. To For histological 
studies, the isolated vessel segments were processed and passed 
through graded alcohol series and xylene, embedded in paraffin 
blocks and sectioned at 5µm thickness were cut using rotary 
microtone and then stained with haemotoxycylin and eosin, cleared 
in xylene and cover slipped in DPX. Histological examination under 
fluorescence microscopy. 
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The mice were divided in four group I-III, each groups consists ten 
mices. 
Group I: Served as control received 0.25% w/v CMC. 
Group II: Serve as cilostazol 30µm 
Group III: serve as clopidogrel 30µm 
STATISTICAL ANALYSIS   
All the results were expressed as mean ± S.E.M. The data from the 
dose response studies were subjected to one-way ANOVA followed 
by post hoc Bonferroni's Multiple Comparison test. 
RESULTS 
When collagen or epinephrine was tested at levels employed below 
in combination, no effect was observed. Epinephrine at high dose 
(70-80 µg) killed 70-80% of challenged mice. This was due to toxic 
effect of drugs which cause pressor effect and ventricular fibrillation. 
The combination of both the aggregating agents within 1 min after 
thrombotic challenge all animals become immobile, develop large 
protruding eyes, began grasping for breath and may be expired after 
2-3min[6-7]. Results have been reported as percentage protection, 
which represents protection against collagen and epinephrine 
induced thrombosis and expressed as: 
 
Percent Protection = [1-(Ptest /Pcontrol))] x 100 
Ptest - number of animals paralyzed/dead in test compound-treated 
group; Pcontrol - number of animals paralyzed/dead in vehicle treated 
group. 
Histological examination of organs of animals that died showed 
massive occlusion of the microcirculation of lungs by platelet 
thrombi. The number of thrombi in the lungs at the time of death 
after the injection was reduced in clopidogrel drug treated mice, 
while in cilostazol treated mice, the number of thrombi were 
relatively more. (Table 1) Show that aqueous solution of cilostazol, 
clopidogrel at the dose employed gave significant protection against 
thrombotic challenge. 
Table 1: Protection of mice from thrombotic challenge (tail vein 
injection of collagen & epinephrine) Effect of antithrombotic 
agents in aqueous medium 








9/10 90%  10%  
2.   Cilostazol  
30 (µg/kg) 
5/10 50% 50 
3. Clopidogrel 
30 (µg/kg) 
4/10 40 60 
 
Fig 1: Lung sections stained with hematoxylin and eosin were digitally imaged using the Leica microscope(40x view inset ) (a) Control, (b) 
control paralysed, (c) Clopidogrel, (d) Cilostazol 
DISCUSSION 
Availability of such a test would facilate preclinical evaluation of 
potentially useful agents for preventing arterial thrombosis [8-11]. 
The mouse antithrombotic test describe here fulfil this needs. It 
employs a small, inexpensive test animals and very small amount of 
aggregating agents to induce thrombosis. The test point is simple 
and the end point is unequivocal. Ten test animals and control can 
be studied in 2 hr.Obviously this method is value for studying 
antithrombotic agents which work primarily by inhibiting platelet 
thromboembolism through their effect on platelet aggregation [13] .In 
addition, Antiplatelet drugs inhibited collagen and epinephrine-
induced thromboembolic death in mice in a dose-dependent manner 
compared with collagen treated control [12].The lethal effect of 
aggregating agonists on mice was known to be caused by massive 
occlusion of the microcirculation of the lung by platelet 
thromboembolism or by vasoconstriction due to the increase of 
TXA2 and prostaglandin E in platelets. Thus, this antithrombotic 
activity can be mediated by inhibition of thromboxane B2 and 
prostaglandin E2, metabolites of arachidonic acid. 
CONCLUSIONS 
In summary we described a simple and inexpensive method of 
evaluating antithrombotic agents .This was in agreement to its 
antithrombotic efficacy as observed in the mice model of collagen 
epinephrine induced pulmonary thromboembolism. Cilostazol was 
also studied for comparison to better validate the experimental 
procedures employed. Clopidogrel exhibited better antithrombotic 
efficacy than cilostazol [14-19]. In the lung sections of mice, the 
number of thrombi was significantly reduced in the clopidogrel 
treated mice as compared to the cilostazol treated and control mice. 
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